# An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.

> **NCT07033026** · PHASE2 · RECRUITING · sponsor: **NGM Biopharmaceuticals, Inc** · enrollment: 136 (estimated)

## Conditions studied

- Colorectal Cancer
- CRC (Colorectal Cancer)
- Cancer Cachexia

## Interventions

- **DRUG:** NGM120 Q4W
- **DRUG:** NGM120 Q8W
- **DRUG:** Placebo given

## Key facts

- **NCT ID:** NCT07033026
- **Lead sponsor:** NGM Biopharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-25
- **Primary completion:** 2027-04
- **Final completion:** 2027-12
- **Target enrollment:** 136 (ESTIMATED)
- **Last updated:** 2026-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07033026

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07033026, "An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07033026. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*